

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: PALESE, Peter et al.

Confirmation No.: 9293

Application No.: 10/821,001

Group Art Unit: 1636

Filed: April 7, 2004

Examiner: GUZO, David

For: RECOMBINANT NEGATIVE
STRAND RNA VIRUS EXPRESSION
SYSTEMS AND VACCINES

Attorney Docket No.: NS104D1C1

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

In order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56, Applicants submit herewith a listing of documents on accompanying Form(s) PTO/SB/08. A copy of each listed document is submitted as required by 37 C.F.R. §1.98.


TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 C.F.R. §1.97(c)(2), after the mailing date of a first office Action on the merits but before the mailing of a final office action. The Commissioner is hereby authorized to charge the required fee under 37 C.F.R. § 1.17(p), and any other fee deemed necessary for consideration of the information disclosure statement, to Deposit Account No. 500479.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Respectfully submitted,

Date: 05-08-08
MEDIMMUNE, LLC
Customer Number: 36577
Telephone: (301) 398-5765
Facsimile: (301) 398-9306

By: 
Michelle Holmes-Son
Attorney for Applicants
Registration No. 47,660